Taiwan-based Biotech Implements Medidata Clinical Cloud
Leading Biopharma Company Adopts Medidata Technology to Bring Operational Efficiencies and Greater Speed to Innovative Clinical Study on Metabolic Disorders
Medidata, a global provider of cloud-based solutions for clinical research in life sciences, announced that TWi Biotechnology, Inc. has selected the Medidata Clinical Cloud® to enhance the speed, quality and productivity of its novel clinical study on metabolic disorders.
TWi Biotechnology, Inc., a fully owned subsidiary of TWi Pharmaceuticals, Inc. based in Taipei, Taiwan, specializes in the development of innovative new drugs for unmet medical needs, especially in the diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. To optimize a Phase II study on metabolic disorders, TWi Biotechnology is implementing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®).
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
